Implementing a Fully Single-Use, Integrated mAb Biosimilars Purification Platform for Next Generation Manufacturing 


Within the biopharmaceutical industry, there is a significant shift toward higher productivity processes resulting in improved economics without compromising robustness. Therefore, integrated continuous production technologies are of greatest interest. 


Next Generation Biopharmaceutical Downstream Process is a European-funded collaborative project that aims at implementing a fully integrated manufacturing platform for biosimilar mAb based on continuous chromatography, in combination with single-use disposable technologies for all unit operations of DSP on pilot/small production scale together with incorporation of advanced analytical tools.


Tune in on Thursday, August 8 at 18:00 KSA and 19:00 UAE. For further information and registration, please visit: